| P2093 | author name string | C Marcocci | |
| | M Leo | |
| | F Menconi | |
| | M Marinò | |
| | P Vitti | |
| P2860 | cites work | TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study | Q28263186 |
| | Graves' ophthalmopathy | Q28274196 |
| | Clinical features of Graves' ophthalmopathy in an incidence cohort | Q28275743 |
| | Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid? | Q33348029 |
| | Diagnosis and classification of Graves' disease | Q34397821 |
| | A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. | Q34782210 |
| | Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens | Q35215882 |
| | Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. | Q35606170 |
| | Role of thyroglobulin in the pathogenesis of Graves' ophthalmopathy: the hypothesis of Kriss revisited | Q35785126 |
| | Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism | Q35837670 |
| | TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy | Q36393011 |
| | A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy | Q36817224 |
| | Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited. | Q37460205 |
| | Pathogenesis of Graves' orbitopathy: a 2010 update. | Q37772737 |
| | Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity | Q37829150 |
| | Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy | Q38013216 |
| | Prevalence and natural history of Graves' orbitopathy in the XXI century | Q38099144 |
| | Current insights into animal models of Graves' disease and orbitopathy | Q38101266 |
| | Diagnosis and management of Graves disease: a global overview | Q38152621 |
| | Extrathyroidal manifestations of Graves' disease: a 2014 update | Q38218911 |
| | An update on the medical treatment of Graves' hyperthyroidism. | Q38245840 |
| | The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study | Q39527157 |
| | Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective | Q41457230 |
| | Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy | Q43566137 |
| | Thyroid volume and severity of Graves' orbitopathy | Q43745434 |
| | Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease | Q43758895 |
| | Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism | Q43907362 |
| | Thyroglobulin in orbital tissues from patients with thyroid-associated ophthalmopathy: predominant localization in fibroadipose tissue. | Q44049859 |
| | A treatment strategy for Graves' orbitopathy | Q44252754 |
| | Current Trends in the Management of Graves' Disease* | Q44319055 |
| | Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation | Q44356261 |
| | Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. | Q45096631 |
| | Radioisotopic thyroidolymphography in patients with Graves' disease | Q45146355 |
| | Reevaluating thyrotropin receptor-induced mouse models of graves' disease and ophthalmopathy. | Q45149782 |
| | Treatment of Graves' disease and the course of ophthalmopathy | Q45235961 |
| | Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. | Q48560620 |
| | Comparison of RA 131I treatment protocols for Graves' disease. | Q53712862 |
| | Total thyroidectomy in the management of thyrotoxic and euthyroid Graves' disease. | Q53775595 |
| | Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism | Q57482592 |
| | Effect of Abnormal Thyroid Function on the Severity of Graves' Ophthalmopathy | Q67657511 |
| | Ophthalmopathy and thyroid stimulation | Q69373946 |
| | Studies on the occurrence of ophthalmopathy in Graves' disease | Q69606497 |
| | Effect on exophthalmos of various methods of treatment of Graves' disease | Q71858707 |
| | Surgical treatment of Graves' disease: subtotal or total thyroidectomy? | Q71866802 |
| | Retrospective evaluation of subtotal and total thyroidectomy in Graves' disease with and without endocrine ophthalmopathy | Q72144883 |
| | Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? | Q72414211 |
| | The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study | Q73231271 |
| | Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment | Q73516641 |
| | Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy | Q73922120 |
| | Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy | Q74010201 |
| | Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves' disease | Q74599353 |
| | MANAGEMENT OF THYROTOXICOSIS IN PATIENTS WITH OPHTHALMOPATHY: ANTITHYROID REGIMEN DETERMINED PRIMARILY BY OCULAR MANIFESTATIONS | Q77185574 |
| | Development of an animal model of autoimmune thyroid eye disease | Q77320743 |
| | Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids | Q79771160 |
| | Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease | Q79885195 |
| | Poorly specific binding of thyroglobulin to orbital fibroblasts from patients with Graves' ophthalmopathy | Q80992008 |
| | Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center | Q86521875 |
| | Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial | Q87111113 |
| P433 | issue | 8 | |
| P304 | page(s) | 809-815 | |
| P577 | publication date | 2015-03-05 | |
| P1433 | published in | Journal of Endocrinological Investigation | Q15766847 |
| P1476 | title | Total thyroid ablation in Graves' orbitopathy | |
| P478 | volume | 38 | |